

10/076,213

DOCKET NO.: P0886CIP1C1

LISTING OF CLAIMS:

1-16. (canceled)

17. (currently amended) A process for minimizing thermal aggregation of DNase in a liquid solution comprising:

a) introducing a DNase aggregation-inhibiting amount of sugar to a solution comprising a human DNase, and

b) ~~wherein the~~ elevating the temperature of said DNase solution is ~~subsequently elevated~~ to above 37°C,

wherein and aggregation of said DNase at said elevated temperature is reduced as compared to DNase in said liquid solution without said DNase aggregation-inhibiting amount of sugar.

18. (previously presented) A process according to claim 17, wherein the temperature of said solution is elevated above about 60°C.

19. (previously presented) A process according to claim 17, wherein the pH of said solution is below pH 7.0.

20. (previously presented) A process according to claim 19, wherein said solution is at about pH 6.5.

21. (previously presented) A process according to claim 19, wherein said solution is at about pH 6.

22. (previously presented) A process according to claim 19, wherein said solution is at about pH 5.

10/076,213

DOCKET NO.: P0886C1P1C1

23. (previously presented) A process according to claim 17, wherein said sugar is present in an amount from 50 mg/ml to 200 mg/ml.
24. (currently amended) A process according to claim 17, wherein said sugar is selected from the group consisting of  $\alpha$ -lactose monohydrate, mannitol, trehalose and sucrose
25. (previously presented) The process according to claim 17, further comprising the steps of spray-drying said liquid solution and collecting the spray-dried product as a respirable DNase-containing powder that is therapeutically effective when administered into the lung of an individual.
26. (previously presented) A DNase solution comprising a human DNase and a DNase aggregation-inhibiting amount of sugar wherein said DNase solution is minimally aggregated when said solution is at a temperature greater than 37°C.
27. (previously presented) A DNase solution according to claim 26, wherein the temperature is greater than about 60°C.
28. (previously presented) A DNase solution according to claim 26, wherein the pH of said solution is below 7.0.
29. (previously presented) A DNase solution according to claim 28, wherein said solution is at about pH 6.5.
30. (previously presented) A DNase solution according to claim 28, wherein said solution is at about pH 6.
31. (previously presented) A DNase solution according to claim 26, wherein said sugar is present in an amount from 50 mg/ml to 200 mg/ml.
32. (currently amended) A DNase solution according to claim 26, wherein said sugar is selected from the group consisting of  $\alpha$ -lactose monohydrate, mannitol, trehalose and sucrose.

10/076,213

DOCKET NO.: P0886C1P1C1

33. (currently amended) A composition comprising a therapeutically effective spray-dried respirable DNase-containing powder made from the DNase solution according to claim 26;  
~~wherein said solution is further spray dried to a respirable DNase-containing powder that is~~  
~~therapeutically effective when administered into the lung of an individual.~~